The country exported this time 1,366,400 doses of the drug, according to the institution’s profile on Twitter, dedicated to research, technological development, production and commercialization of biotechnological and pharmaceutical preparations.
On September 20, as part of the visit to Havana of Vietnam’s President Nguyen Xuan Phuc, both nations signed the Contract for the Supply and Distribution of five million doses of Abdala vaccine against the SARS-CoV-2 coronavirus.
The general director of the CIGB, Marta Ayala, said after the ceremony that they worked on the completion of the documentation required to approve the emergency use of that drug in Vietnam, and underscored the endorsement of Polyvac, considered one of the most prestigious agencies in the Asian region.
In her statements, Ayala explained that the Cuban vaccine with a three-dose schedule with an interval of 14 days between each application, will be used in both adult and child population in Hanoi.
The productive platform of the drug is used by the CIGB in other vaccines registered in over 30 countries and is certified by the World Health Organization (WHO).
Abdala, the first vaccine in Cuba and Latin America, showed 90 percent effectiveness in severe patients and against the Delta variant of Covid-19, and 92.28 percent effectiveness against symptomatic disease.
The doses elaborated so far reached 40 million, a figure that constitutes a milestone for science in Cuba, the CIGB pointed out on Wednesday on Twitter.
On board the plane that on September 25 took Xuan Phuc back to Vietnam after a trip to Cuba and to the United Nations, five million doses of Abdala arrived first.
On the same flight, there were another 150,000 doses donated by Cuba, which will transfer to Vietnam the technology to produce them.